Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation
- PMID: 6333639
- DOI: 10.1038/311750a0
Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation
Abstract
Major histocompatibility complex (MHC) class I molecules can function as specific target antigens in T-cell-mediated cytotoxity. In addition, T cells can kill target cells through non-MHC antigens, for example, virally infected cells, if the target and effector cells express the same MHC class I antigens. Consequently, quantitative and/or qualitative variations in the expression of the H-2/HLA antigens on the target cells could interfere with MHC-restricted immune reactions. We have reported that the AKR leukaemia cell line K36.16, a subline of K36 (ref. 3), on which the H-2Kk antigen cannot be detected, is resistant to T-cell lysis and grows very easily in AKR mice. Other AKR tumour cell lines, like 369, which have a relatively large amount of H-2Kk on their surface, are easily killed by T cells in vitro and require a much larger inoculum to grow in vivo. Monoclonal antibodies against H-2Kk, but not against H-2Dk, prevented the killing by T cells. This suggests that some tumour cells grow in vivo because tumour-associated antigen(s) cannot be recognized efficiently by the host's immune system, due to the absence of MHC molecules which would function as restriction elements for T-cell cytotoxicity. We have tested this hypothesis by introducing the H-2Kk gene into the H-2Kk-deficient AKR tumour cell line K36.16 and have now demonstrated directly the biological relevance of H-2Kk antigen expression in the regulation of the in vivo growth of this tumour cell line.
Similar articles
-
Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene.J Immunol. 1989 Dec 1;143(11):3835-43. J Immunol. 1989. PMID: 2584720
-
Resistance to cell-mediated cytotoxicity is correlated with reduction of H-2K gene products in AKR leukemia.Immunogenetics. 1982;16(3):257-64. doi: 10.1007/BF00343314. Immunogenetics. 1982. PMID: 6982849
-
The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16.Immunology. 1991 Feb;72(2):213-8. Immunology. 1991. PMID: 1901830 Free PMC article.
-
Variation in MHC antigenic profiles of tumor cells and its biological effects.Immunol Rev. 1981;60:85-127. doi: 10.1111/j.1600-065x.1981.tb00363.x. Immunol Rev. 1981. PMID: 6171505 Review. No abstract available.
-
The role of surface HLA-A,B,C molecules in tumour immunity.Cancer Surv. 1992;13:101-27. Cancer Surv. 1992. PMID: 1423320 Review.
Cited by
-
Altered regulation of MHC class I genes in different tumor cell lines is reflected by distinct sets of DNase I hypersensitive sites.EMBO J. 1989 Aug;8(8):2297-304. doi: 10.1002/j.1460-2075.1989.tb08356.x. EMBO J. 1989. PMID: 2507317 Free PMC article.
-
Prospects for the therapeutic use of anticancer vaccines.Drugs. 1999 Mar;57(3):309-25. doi: 10.2165/00003495-199957030-00004. Drugs. 1999. PMID: 10193685 Review.
-
Cancer of the cervix: prospects for immunological control.Int J Exp Pathol. 1991 Apr;72(2):239-51. Int J Exp Pathol. 1991. PMID: 1849733 Free PMC article. Review. No abstract available.
-
Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen.Cancer Immunol Immunother. 2007 Feb;56(2):165-80. doi: 10.1007/s00262-006-0179-x. Epub 2006 Jun 7. Cancer Immunol Immunother. 2007. PMID: 16758205 Free PMC article.
-
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.J Exp Med. 1994 Apr 1;179(4):1215-24. doi: 10.1084/jem.179.4.1215. J Exp Med. 1994. PMID: 7908321 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
